AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.71B
1-Year Est. Return
374.45%
This Fund
S&P 500
1 Year Est. Return
+374.45%
AUM
$1.71B
AUM Growth
+$313M
(+23%)
Holding
118
Top Buys
| 1 | +$28.3M | |
| 2 | +$26.6M | |
| 3 | +$20.4M | |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$19.6M |
| 5 |
Erasca
ERAS
|
+$17.1M |
Top Sells
| 1 | +$58.6M | |
| 2 | +$16.9M | |
| 3 | +$14.8M | |
| 4 |
ACLX
Arcellx
ACLX
|
+$14.2M |
| 5 |
BridgeBio Pharma
BBIO
|
+$12.3M |
Sector Composition
| 1 | Healthcare | 97.1% |
| 2 | Financials | 0.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$6.19B
| $108M | 6.34% |
1,284,926
+50,000
|
|
||
|
2
Xenon Pharmaceuticals
XENE
$5.18B
| $97.4M | 5.71% |
1,675,000
+425,000
|
|
||
|
3
Erasca
ERAS
$4.01B
| $86.6M | 5.08% |
5,350,000
+1,450,000
|
|
||
4
Insmed
INSM
$22.4B
| $78.5M | 4.6% |
480,000
+30,000
|
|
||
5
Roivant Sciences
ROIV
$20.5B
| $77.6M | 4.55% |
2,800,000
+1,100,000
|
|
||
6
Spyre Therapeutics
SYRE
$6.31B
| $64.5M | 3.78% |
1,279,134
-153,457
|
|
||
|
CNTA
7
Centessa Pharmaceuticals
CNTA
$6.17B
| $55.6M | 3.26% |
1,400,000
+799,448
|
|
||
8
Praxis Precision Medicines
PRAX
$7.55B
| $54.8M | 3.21% |
170,000
-15,000
|
|
||
9
AnaptysBio
ANAB
$1.5B
| $52.1M | 3.06% |
940,000
+495,308
|
|
||
10
Alkermes
ALKS
$7.09B
| $47.7M | 2.8% |
1,350,000
+350,000
|
|
||
11
Cytokinetics
CYTK
$9.7B
| $46.2M | 2.71% |
700,483
-99,517
|
|
||
|
ABVX
12
Abivax
ABVX
$6.58B
| $45.1M | 2.64% |
405,000
-100,000
|
|
||
13
Teva Pharmaceuticals
TEVA
$37.8B
| $42.2M | 2.47% |
1,400,000
|
|
||
|
ACLX
14
DELISTED
Arcellx
ACLX
| $41.7M | 2.44% |
362,764
-160,961
|
|
||
15
Nuvalent
NUVL
$7.18B
| $30.7M | 1.8% |
300,000
-22,633
|
|
||
|
TERN
16
DELISTED
Terns Pharmaceuticals
TERN
| $29.7M | 1.74% |
562,631
+12,631
|
|
||
17
Dianthus Therapeutics
DNTH
$4.6B
| $29.4M | 1.72% |
350,000
+235,000
|
|
||
18
Lexeo Therapeutics
LXEO
$355M
| $29M | 1.7% |
5,050,211
+1,850,211
|
|
||
19
Cogent Biosciences
COGT
$5.51B
| $28.9M | 1.69% |
750,000
+400,000
|
|
||
20
Madrigal Pharmaceuticals
MDGL
$10.8B
| $28.8M | 1.69% |
55,000
+23,869
|
|
||
21
Sutro Biopharma
STRO
$411M
| $26.6M | 1.56% |
1,069,519
+321,137
|
|
||
22
Forte Biosciences
FBRX
$354M
| $26.2M | 1.54% |
1,011,890
+22,400
|
|
||
|
ORKA
23
Oruka Therapeutics
ORKA
$3.41B
| $24.5M | 1.44% |
499,673
-302,669
|
|
||
24
Trevi Therapeutics
TRVI
$1.9B
| $23.9M | 1.4% |
2,000,172
-150,000
|
|
||
25
Ovid Therapeutics
OVID
$452M
| $23.6M | 1.38% |
10,636,318
+3,486,318
|
|